Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial
Top Cited Papers
- 3 December 2010
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 13 (3), 258-267
- https://doi.org/10.1111/j.1463-1326.2010.01350.x
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- The Metabolism and Disposition of the Oral Dipeptidyl Peptidase-4 Inhibitor, Linagliptin, in HumansPublished by American Society for Pharmacology & Experimental Therapeutics (ASPET) ,2010
- Binding to dipeptidyl peptidase‐4 determines the disposition of linagliptin (BI 1356) – investigations in DPP‐4 deficient and wildtype ratsBiopharmaceutics & Drug Disposition, 2009
- Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase‐4 inhibitor in male type 2 diabetes patientsDiabetes, Obesity and Metabolism, 2009
- Novel Approaches to the Treatment of Type 2 DiabetesJournal of Pharmacy Practice, 2009
- Metformin, Sulfonylureas, or Other Antidiabetes Drugs and the Risk of Lactic Acidosis or HypoglycemiaDiabetes Care, 2008
- Robust improvements in fasting and prandial measures of β‐cell function with vildagliptin in drug‐naïve patients: analysis of pooled vildagliptin monotherapy databaseDiabetes, Obesity and Metabolism, 2008
- 8-(3-(R)-Aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a Highly Potent, Selective, Long-Acting, and Orally Bioavailable DPP-4 Inhibitor for the Treatment of Type 2 DiabetesJournal of Medicinal Chemistry, 2007
- Chronic Inhibition of Dipeptidyl Peptidase-4 With a Sitagliptin Analog Preserves Pancreatic β-Cell Mass and Function in a Rodent Model of Type 2 DiabetesDiabetes, 2006
- Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrationsJournal of Clinical Endocrinology & Metabolism, 1993
- Glucagonostatic and insulinotropic action of glucagonlike peptide I-(7-36)-amideDiabetes, 1989